Gilead Sciences Non-GAAP EPS of $1.58 beats by $0.06, revenue of $6.26B beats by $390M, raises FY22 EPS guidance
Gilead Sciences press release (NASDAQ:GILD): Q2 Non-GAAP EPS of $1.58  beats by $0.06.
Revenue of $6.26B (+0.6% Y/Y)  beats by $390M.
Total second quarter 2022 revenue increased 1% to $6.3 billion compared to the same period in 2021, primarily due to increased sales in HIV and oncology products, offset partially by decreased sales of Veklury (remdesivir) and hepatitis C virus (âHCVâ) products.

Shares +0.7%.
Biktarvy Sales Increased 28% Year-Over-Year to $2.6 billion.
Oncology Sales Increased 71% Year-Over-Year to $527 million.

For the full-year, Gilead has updated its guidance and now expects:

Total product sales between $24.5 billion and $25.0 billion, compared to $23.8 billion and $24.3 billion previously.
Total product sales, excluding Veklury, between $22.0 billion to $22.5 billion, compared to $21.8 billion and $22.3 billion previously.
Total Veklury sales of approximately $2.5 billion, compared to approximately $2.0 billion previously.
Non-GAAP earnings per share between $6.35 and $6.75, compared to $6.20 and $6.70 previously vs. $6.58 consensus.
Earnings per share between $2.90 and $3.30, compared to $3.00 and $3.50 previously.